These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 16391620

  • 1. The use of subretinal triamcinolone acetonide in the management of neovascular age-related macular degeneration: a pilot study.
    Kertes PJ, Coupland SG.
    Can J Ophthalmol; 2005 Oct; 40(5):573-84. PubMed ID: 16391620
    [Abstract] [Full Text] [Related]

  • 2. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
    Augustin AJ, Schmidt-Erfurth U.
    Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209
    [Abstract] [Full Text] [Related]

  • 3. Indocyanine green-mediated photothrombosis with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration.
    Arevalo JF, Garcia RA, Mendoza AJ.
    Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1180-5. PubMed ID: 15906068
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of subretinal triamcinolone acetonide in patients with exudative age-related macular degeneration.
    Kozak I, Cheng L, Falkenstein I, Tammewar AM, Freeman WR.
    J Ocul Pharmacol Ther; 2007 Feb; 23(1):46-53. PubMed ID: 17341150
    [Abstract] [Full Text] [Related]

  • 5. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration.
    Neovascular Age-Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy (NAPP) Trial Research GroupJohns Hopkins University, Baltimore, Maryland, USA., Gilson MM, Bressler NM, Jabs DA, Solomon SD, Thorne JE, Wilson DJ.
    Ophthalmology; 2007 Sep; 114(9):1713-21. PubMed ID: 17822977
    [Abstract] [Full Text] [Related]

  • 6. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration.
    Ergun E, Maár N, Ansari-Shahrezaei S, Wimpissinger B, Krepler K, Wedrich A, Stur M.
    Am J Ophthalmol; 2006 Jul; 142(1):10-16. PubMed ID: 16815246
    [Abstract] [Full Text] [Related]

  • 7. Indocyanine green-mediated photothrombosis with and without intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration: a pilot study.
    Arevalo JF, Mendoza AJ, Fernández CF.
    Retina; 2005 Sep; 25(6):719-26. PubMed ID: 16141859
    [Abstract] [Full Text] [Related]

  • 8. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
    Hatta Y, Ishikawa K, Nishihara H, Ozawa S, Ito Y, Terasaki H.
    Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
    Jonas JB.
    Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
    [Abstract] [Full Text] [Related]

  • 10. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin.
    Van de Moere A, Sandhu SS, Kak R, Mitchell KW, Talks SJ.
    Ophthalmology; 2005 Nov; 112(11):1896-903. PubMed ID: 16214216
    [Abstract] [Full Text] [Related]

  • 11. Photodynamic therapy combined with low-dose intravitreal triamcinolone acetonide for age-related macular degeneration refractory to photodynamic therapy alone.
    Iwama D, Otani A, Sasahara M, Yodoi Y, Gotoh N, Tamura H, Tsujikawa A, Yoshimura N.
    Br J Ophthalmol; 2008 Oct; 92(10):1352-6. PubMed ID: 18662914
    [Abstract] [Full Text] [Related]

  • 12. Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study.
    Arevalo JF, Sanchez JG, Garcia RA, Wu L, Berrocal MH, Rodriguez FJ, Rodríguez A, Novoa LA, Garcia-Amaris R.
    Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1673-80. PubMed ID: 17619895
    [Abstract] [Full Text] [Related]

  • 13. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X, Li J, Hu X, Yu S, Pan J, Tang S.
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [Abstract] [Full Text] [Related]

  • 14. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results.
    Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P, Billson F.
    Arch Ophthalmol; 2003 May; 121(5):667-73. PubMed ID: 12742844
    [Abstract] [Full Text] [Related]

  • 15. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmina M, Dehghan MH, Moradian S.
    BMC Ophthalmol; 2007 Jun 07; 7():10. PubMed ID: 17555600
    [Abstract] [Full Text] [Related]

  • 16. Combined photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: effect of initial visual acuity on treatment response.
    Schadlu R, Kymes SM, Apte RS.
    Graefes Arch Clin Exp Ophthalmol; 2007 Nov 07; 245(11):1667-72. PubMed ID: 17583819
    [Abstract] [Full Text] [Related]

  • 17. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
    Veritti D, Sarao V, Lanzetta P.
    J Ocul Pharmacol Ther; 2013 May 07; 29(4):437-41. PubMed ID: 23215753
    [Abstract] [Full Text] [Related]

  • 18. Time-course and characteristic morphology of retinal changes following combination of verteporfin therapy and intravitreal triamcinolone in neovascular age-related macular degeneration.
    Lie S, Aue A, Sacu S, Simader C, Polak K, Schmidt-Erfurth U.
    Acta Ophthalmol; 2010 Mar 07; 88(2):212-7. PubMed ID: 19016662
    [Abstract] [Full Text] [Related]

  • 19. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial.
    Maberley D, Canadian Retinal Trials Group.
    Ophthalmology; 2009 Nov 07; 116(11):2149-57.e1. PubMed ID: 19748675
    [Abstract] [Full Text] [Related]

  • 20. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results.
    Lee J, Freeman WR, Azen SP, Chung EJ, Koh HJ.
    Retina; 2007 Nov 07; 27(9):1205-13. PubMed ID: 18046226
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.